fda approval semaglutide mash 🎉Exciting news that is now approved for (aka fatty liver disease) “At week 72, the primary efficacy endpoint was based on histology (liver biopsy results). Interim results showed 63% Semaglutide as a MASH Treatment:

Contrave may be beneficial for individuals struggling with cravings and emotional eating triggered by anxiety and stress factors whereas Wegovys ability to induce prolonged feelings of fullness could result in sustainable weight loss outcomes in the long run

All three trials were sponsored by the manufacturer (Bayer), raising the possibility of reporting bias

WHAT TO EXPECT: MONTH-BY-MONTH TIMELINE GLP-1 therapy is a gradual process

This is not a magic shot that lets you eat whatever you want

Sign up now and stay informed

Our programs feature flat-rate pricing with zero hidden fees, zero consultation charges, and no dose-change surcharges